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Abstract
Background:  Herba Cistanches (Roucongrong) is effective in treating Shenxu Zheng ('kidney-
deficiency syndrome'). However, the mechanisms and systemic metabolic responses to the herbal
intervention are unclear.
Methods: Using GC-MS-based metabolic profiling, we investigated the metabolic responses to
Herba Cistanches intervention in a rat model of the hydrocortisone-induced 'kidney-deficiency
syndrome'.
Results: The metabolic profiles of the rats after hydrocortisone injection deviated from the pre-
dose metabolic state at different time points, ranging from day 1 to day 10, whereas the metabolic
profiles of the rats treated with both hydrocortisone and water extract of Herba Cistanches
returned to the pre-dose state on day 10.
Conclusion:  The intervention of Herba Cistanches caused a systemic recovery from the
hydrocortisone-induced metabolic perturbation in rats. This study also demonstrates that
metabolic profiling is useful in studying therapeutic mechanisms of herbal medicines.
Background
Through modulation of biochemical reactions, control
mechanisms, and enzyme activities, many drugs or chem-
icals cause fluctuation of metabolites present in single
cells, tissues or body fluids [1]. Metabolic profiling, i.e.
probing metabolites of low molecular weight (MW <
1000 Da) by means of advanced analytical instrument
coupled with multivariate statistics, can show systemic
responses of living systems to xenobiotics. It is also tech-
nically feasible to catalogue all the multifactorial heritable
and environmentally influenced metabolic profiles of an
organism, including the physiopathological conse-
quences of toxin and/or disease-induced disturbances or
disequilibria in metabolic regulatory network on a sys-
temic level. To date, metabolic profiling has been estab-
lished in screening, diagnosis, prognosis of diseases [2-4],
and safety evaluation of certain drugs and chemicals [5-
11].
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Nuclear magnetic resonance (NMR) [12] and mass spec-
trometry (MS) [13], applied alone or in combination,
have been used in profiling and characterizing metabolic
consequences of toxin and/or disease-induced distur-
bances. NMR, which does not require tedious sample pre-
processing, is a fast and simple method to obtain intrinsic
information from complex and intact biological samples.
On the other hand, the wide application of hyphenated
MS in metabolic profiling is due to its high sensitivity and
availability [14,15]. Notably, GC-MS-based metabolic
profiling has been used in discovering mechanisms of
drugs and herbicides in vivo, biomarkers of diseases [16]
and effects of altered gene expression on metabolism, and
monitoring performance of organisms in biotechnologi-
cal applications [17-20].
Herba Cistanches (Roucongrong), a common Chinese tonic
herb which grows in desert, exhibits marked activities for
improving memory [21] and/or sexual potency [22], free
radical scavenging, anti-aging [23-26] and neuroprotec-
tion [27,28]. For centuries, Herba Cistanches has been
effectively used in treating Shenxu Zheng ('kidney-defi-
ciency syndrome') [29]. Recently Herba Cistanches was
demonstrated to have ameliorated hydrocortisone-
induced kidney disorders [30]; however, its metabolic
consequences are not clear. Our previous study [31]
found that metabolic profiles of rats exposed to hydrocor-
tisone at a high dosage (i.e. an animal model for the 'kid-
ney-deficiency syndrome') [32], showed a unique
biochemical pattern of endogenous metabolites in urine.
These results inspired us to study the mechanisms of con-
sistent biochemical changes following hydrocortisone
modification, using GC-MS-based metabolic profiling to
investigate whether Herba Cistanches could reverse or
counteract aberrant metabolic effects of hydrocortisone.
Methods
Materials and instrument
Herba Cistanches was purchased from Shanghai Leiyun-
shang Pharmaceutical Co Ltd (China) and identified as
Cistanche deserticola Y C Ma by Dr Mengyue Wang (Labo-
ratory of Pharmacognostics, School of Pharmacy, Shang-
hai Jiao Tong University) according to a standard protocol
[33]. Hydrocortisone solution for injection (0.5%) was
purchased from Shanghai Xinyi Pharmaceutical Co
(China). The derivatizing reagents were N-methyl-N-tri-
methylsilyltrifluoroacetamide (MSTFA) (Sigma-Aldrich
Inc, USA) and Trimethyliodosilane (TMSI) (Sigma-
Aldrich Inc, USA) mixed at a ratio of 1000:1. All reagents
used in the experiment were of analytical grade. Ultra-
pure water was prepared with Millipore purification sys-
tem (18.2 MΩ, USA). Metabolic cages were purchased
from Suzhou Fengshi Laboratory Animal Experiment Co
Ltd (China).
Preparation of Herba Cistanches extract
Five hundred grams of coarsely pulverized plant material
was refluxed with 2 L of ultra-pure water for 2 hours. After
filtration, the extract was evaporated to about one tenth of
the original volume on a Buchi rotary evaporator and was
diluted to 250 mL in a volumetric flask with ultra-pure
water. The final concentration of crude Herba Cistanches
extract was 2 g/mL.
Dosage and sampling
The handling of all animals in this study conformed to the
national guidelines and was performed at the Center for
Laboratory Animals, Shanghai University of Traditional
Chinese Medicine, Shanghai, China. A total of 19 nine-
week-old male Wistar rats were purchased from Shanghai
Laboratory Animal Co Ltd (China). All animals were kept
at a barrier system with regulated temperature (20–22°C)
and humidity (60 ± 10%), and on a 12 hour dark/light
cycle with lights on at 8:00 am. The rats were given ad libi-
tum food and water. After two weeks' acclimation, the ani-
mals were transferred to individual metabolic cages and
randomly divided into three groups: (1) treatment group
(n = 7) in which hydrocortisone (5%) was injected i.p. at
1.5 mg/100 g of body weight followed by oral administra-
tion of Herba Cistanches extract for 10 days; (2) model
group (n = 7) in which hydrocortisone (5%) was injected
i.p. at 1.5 mg/100 g once daily for 10 days; and (3) control
group (n = 5) in which the vehicle was injected i.p. at
about 0.6 mL for 10 days [31]. Herba Cistanches was
administered to the treatment group at a dose of 20 g/kg
following the recommendation by Shen et al. [30].
Twenty-four hour urine samples were collected at specific
time intervals: pre-dose (-24 – 0 h), day 1 (0 – 24 h), day
3, day 7, and day 10. All the urine samples were centri-
fuged (6383 × g, LG 16-W, Beijing Jingli Centrifuge Co
Ltd, China) for 10 minutes to remove suspended debris
and immediately stored at -80°C for subsequent GC-MS
analysis.
Sample preparation and GC-MS
GC-MS was performed according to our previous study
with minor modifications [31]. Briefly, each 0.5 µL aliq-
uot of trimethylsilyl (TMS) derivatized analyte was
injected into a fused-silica capillary column (17 m × 220
µm inside diameter, 0.11 µm film thickness; HP Ultra-1,
Agilent J&W Scientific, USA). GC-MS was conducted on a
hyphenated PerkinElmer gas chromatograph and Turbo-
Mass-Autosystem XL mass spectrometer (PerkinElmer Inc,
USA).
Data processing and multivariate analysis
The GC-MS data were converted into NetCDF format
through DataBridge (PerkinElmer Inc, USA). Custom
scripts were run in MATLAB 7.0 (The MathWorks Inc,
USA) to perform baseline correction, peak deconvolutionChinese Medicine 2008, 3:3 http://www.cmjournal.org/content/3/1/3
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and alignment, internal standard exclusion, and normali-
zation to the total sum of the chromatogram. The result-
ant 3-dimensional matrix encompassing arbitrary peak
index (paired retention time-m/z), samples (observa-
tions), and normalized peak areas (variables) were
imported into the SIMCA-P 11.0 software package (Umet-
rics, Sweden) for multivariate analysis.
Mean-centering was performed column-wise to remove
the offsets. All the measured metabolites were treated on
an equal level with auto-scaling (scaled to unit variance)
prior to multivariate analysis. Principal component anal-
ysis (PCA) was performed using the SIMCA-P 11.0 soft-
ware to reveal the general clustering, grouping, and trends
among the subjects without prior knowledge. The first
principal component (PC1) represents the most variance
in the data. The second principal component (PC2) is
orthogonal to PC1, and represents maximum amount of
variance not explained by PC1. The remaining principal
components were constructed in the same manner. Mean-
while, mean trajectories of PCA scores were used to pro-
vide a dynamic indication for the onset, progression, and/
or recovery of the syndrome through time. Correlation
coefficients from the partial least squares – discriminant
analysis (PLS-DA) were used to rank the importance of
each variable to further capture the differentially
expressed metabolites accountable for the separation
between groups. PLS-DA is derived from the partial least
squares (PLS) method which is a generalized multiple
regression method dealing with multiple collinear predic-
tor and response variables [34]. The PLS-DA was con-
ducted using the SIMCA-P 11.0 software [35]. A typical 7-
round cross-validation was performed. One seventh of the
samples were excluded from the model in each round so
as to validate the model. This procedure was repeated in
an iterative manner for cross-validation until each sample
had been excluded once.
Univariate analysis
The differentially expressed metabolites identified from
multivariate analysis were also verified in the MATLAB 7.0
software (The MathWorks Inc, USA) by nonparametric
Kruskal-Wallis test with a significance level at P < 0.05.
Results and Discussion
Interpretation of GC-MS spectra
Typical GC-MS total ion current (TIC) chromatograms of
rat urine on day 10 from the treatment group, model
group and control group are shown in Figure 1. Using our
optimized GC-MS analysis protocol in association with a
software-based peak deconvolution procedure, a total of
117 individual metabolites were consistently detected in
Typical GC-MS total ion current (TIC) chromatograms of urine on day 10 from the treatment group (A), model group (B) and  control group (C) Figure 1
Typical GC-MS total ion current (TIC) chromatograms of urine on day 10 from the treatment group (A), 
model group (B) and control group (C).Chinese Medicine 2008, 3:3 http://www.cmjournal.org/content/3/1/3
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at least 90% of the urine samples. Compound identifica-
tion of peaks of interest was performed by comparing the
mass spectral fragment against the NIST (National Insti-
tute of Standards and Technology) reference libraries,
Wiley libraries and reference standards. We were able to
verify 23 out of the 117 metabolites (20%), the majority
of which were amino acids, polyamines, fatty acids,
purines and adrenal hormones that are mainly involved
in energy metabolism, lipid metabolism and amino acid
metabolism.
Time-dependent changes in urine samples
The mean trajectories of the PCA scores derived from the
model group and treatment group were illustrated in Fig-
ure 2. Transient shift in the trajectory plot revealed the
dynamic progress of the 'kidney-deficiency syndrome'
induced by hydrocortisone alone or in combination with
Herba Cistanches treatment. In the model group, meta-
bolic patterns on day 1 and day 3 were different from
those on day 7 and day 10, suggesting that the metabolic
regulatory network on day 1 and day 3 might have under-
gone a transient period with high fluctuations, and that
the perturbed network might have been restored on day 7
and day 10 which ultimately led to a stable pattern close
to the pre-dose state. Analogously, the fact that metabolic
pattern of day 1 and day 3 obviously deviated from that of
pre-dose in the treatment group indicated the dominant
'kidney-deficiency syndrome' state. In this period, the
effects of hydrocortisone were probably dominant over
those of the Herba Cistanches extract. These findings were
consistent with the general observation that rats from
both groups showed less activity on day 1 and day 3. Inter-
estingly, the metabolic patterns on day 7 and day 10 grad-
ually and significantly approached the pre-dose state,
suggesting that Herba Cistanches had some counteracting
or therapeutic effects on the rats exposed to hydrocorti-
sone. These results support the clinical findings that Herba
Cistanches  is effective in treating the 'kidney-deficiency
syndrome'. In general, both trajectories provide a visual,
overall and dynamic picture of the onset, progression and
recovery of the 'kidney-deficiency syndrome'.
Comparative metabolic analysis of urine samples
To better understand the metabolic effects of hydrocorti-
sone, we compared the metabolic profiles obtained from
the control, model and treatment groups. General cluster-
ing of the three groups can be readily observed at various
time points, i.e. pre-dose, day 3 and day 10 (Figure 3).
Mean trajectory of PC1 vs PC2 scores for urine samples from the model group (-● -) and treatment group (--● --) Figure 2
Mean trajectory of PC1 vs PC2 scores for urine samples from the model group (-● -) and treatment group (--
● --). Each dot denotes a mean score at different time points, i.e. pre-dose, days 1, 3, 7 and 10. Error bar represents the stand-
ard deviation for each time point obtained by the first principal component.Chinese Medicine 2008, 3:3 http://www.cmjournal.org/content/3/1/3
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Comparison of metabolic profiles from the control group (black diamond), model group (red diamond), and treatment group  (blue diamond) at different time points: pre-dose (A), day 3 (B) and day 10 (C) Figure 3
Comparison of metabolic profiles from the control group (black diamond), model group (red diamond), and 
treatment group (blue diamond) at different time points: pre-dose (A), day 3 (B) and day 10 (C). Each dot in the 
PCA scores plot represents the data obtained from a rat.
Table 1: A list of metabolites included in the metabolic profiling of the present study
Compounds M/H/0 D/H/0 M/H/3 D/H/3 kw (P) corr coeffs M/H/10 D/H/10
Tyramine 1.1 1.1 2.8 2.8 0.0074 0.66 2.1 1.2
Dopamine -1.5 1.0 3.0 2.8 0.0045 0.88 1.7 1.4
Tetradecanoic acid 1.2 1.2 3.0 3.0 0.0045 0.65 3.0 1.0
Glycine 1.4 -1.3 2.8 2.1 0.0074 0.77 1.6 1.3
Galacturonic acid 1.4 1.3 3.0 3.0 0.0045 0.88 1.8 1.5
Hexadecanoic acid -1.0 1.2 2.2 2.5 0.0118 0.58 2.1 1.0
Acetate -1.4 -1.3 -3.0 -3.0 0.0045 -0.71 -2.6 -1.1
Uridine 1.4 1.4 2.5 1.3 0.0045 0.67 1.8 1.1
Oleic acid -1.1 -1.1 2.2 -1.1 0.0118 0.67 1.2 1.8
3-Hydroxyproline -1.1 1.0 2.0 1.6 0.0284 0.64 2.9 1.3
Octadecanoic acid 1.3 -1.3 2.5 2.5 0.0045 0.79 1.8 1.1
Noradrenaline -1.4 -1.3 2.5 1.0 0.0045 0.77 2.8 1.1
Alanine 1.0 1.0 2.5 2.2 0.0045 0.67 1.5 1.0
Gulonate -1.1 1.2 1.9 1.3 0.0424 0.53 2.8 1.4
4-(3-Hydroxy-phenyl)-butyric acid 1.2 1.3 2.1 -1.7 0.0424 0.86 1.1 1.1
2-Monopalmitin -1.3 -1.3 2.5 2.4 0.0045 0.73 1.2 1.2
1-Monoeleoylglycerol 1.1 1.1 -1.9 1.6 0.2912 0.6 -1.3 -1.3
Cholesterol 1.3 1.3 2.5 2.5 0.0045 0.62 1.7 1.0
Butanoic acid 1.1 -1.2 3.0 3.0 0.0045 0.83 1.9 1.1
D-galactose -1.4 -1.4 -1.8 -1.8 0.0618 -0.6 -1.3 -1.3
Stearin -1.0 1.2 -1.3 -1.6 0.4649 0.52 -1.4 -1.5
Eicosanoic acid -1.0 1.1 1.8 1.9 0.0618 0.85 1.4 1.1
Tyrosine 1.3 -1.0 2.8 1.2 0.0074 0.88 2.3 1.4
Note: The correlation coefficients (corr coeffs) of all compounds were calculated from a cross-validated PLS-DA model (Q2Ycum = 0.899, a 
satisfactory model using two components) on day 3 between the control group and model group with or without Herba Cistanches treatment. 
Additionally, the fold changes were tested by the nonparametric Kruskal-Wallis test. Kw (P) denotes the P values of the test. H = control group, M 
= model group, D = treatment group. For example, H/M/0 represents the relative fold changes (model to control) at the pre-dose state.Chinese Medicine 2008, 3:3 http://www.cmjournal.org/content/3/1/3
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While there is no separation tendency in pre-dose urine
profiles, the metabolic profiles deviated from those of the
control group on day 3 after hydrocortisone exposure. The
metabolic perturbation by hydrocortisone appeared in
both the model and treatment groups. However, after a
consecutive 7-day treatment with Herba Cistanches, meta-
bolic profiles of the treatment group became comparable
to those of the control group again, indicating that Herba
Cistanches did effectively restore the perturbed metabo-
lism.
Differential identification of metabolic profiles
A cross-validated PLS-DA model was used to identify the
key metabolites in different metabolic profiles for easier
differentiation between the control group rats and model
group (i.e. hydrocortisone-induced) rats with or without
Herba Cistanches treatment on day 3 (Table 1). Fold
changes in relative concentration of each key metabolite
between groups were determined and the corresponding
visualization of the changes between groups at pre-dose,
day 3 and day 10 was produced (Figure 4). As shown in
Figure 4 and Table 1, while most of the endogenous
metabolites significantly increased or decreased in the
model group, those in the treatment group underwent a
transient period as observed on day 1 and day 3 and grad-
ually approached the control (normal) level. For example,
as compared to the slight variation (1.1–1.5 times) of the
metabolites in the treatment group on day 10, the greatly
enhanced levels (1.7–3.0 times) of urinary tyrosine,
tyramine, dopamine, and noradrenaline were observed in
the model group throughout the experiment. Our previ-
ous study showed that the enhanced catecholamine
metabolism induced by glucocorticoids resulted in over-
consumption of immune functions, thereby leading to
the 'kidney-deficiency syndrome' [31]. Herba Cistanches, a
tonic herb which improves the immune system [36], may
counteract against some effects of hydrocortisone. Herba
Cistanches may also be able to restore a normal metabolic
regulatory network. Further experiments with different
approaches such as molecular biology, cell biology and
plant chemistry are required to delineate the actions of
Herba Cistanches (and its constituents) in the 'kidney-defi-
ciency syndrome'.
Conclusion
The present metabolic profiling study using GC-MS
showed that Herba Cistanches caused a systemic recovery
from the hydrocortisone-induced metabolic perturbation
in rats, an animal model for the 'kidney-deficiency syn-
drome'. This study also demonstrates that metabolic pro-
filing is a useful method to study therapeutic effects of
herbal medicines.
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Fold changes of the key metabolites Figure 4
Fold changes of the key metabolites. Red color denotes 
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